XM does not provide services to residents of the United States of America.
A
A

ACADIA

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Acadia Pharmaceuticals Inc - On Nov 18, Co Involuntarily Terminates COO Brendan Teehan

BRIEF-Acadia Pharmaceuticals Inc - On Nov 18, Co Involuntarily Terminates COO Brendan Teehan Nov 20 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O : ACADIA PHARMACEUTICALS INC - ON NOV 18, CO INVOLUNTARILY TERMINATES COO BRENDAN TEEHAN Source text: [ https://tinyurl.com/53xs6xaj ] Further company coverage: ACAD.O
A

ACADIA Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary

ACADIA Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary ACADIA Pharmaceuticals Inc ACAD.OQ reported quarterly adjusted earnings of 20 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -40 cents. The mean expectation of twenty analysts for the quarter was for earnings of 14 cents per share.
A

U.S. BXP, Hubspot, Qualcomm

U.S. RESEARCH ROUNDUP-BXP, Hubspot, Qualcomm Nov 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including BXP, Hubspot and Qualcomm, on Thursday. HIGHLIGHTS * Aspen Technology Inc AZPN.O : Berenberg cuts to hold from buy * BXP Inc BXP.N : Scotiabank cuts to sector perform from sector outperform * Clearwater Analytics Holdings Inc CWAN.N : JP Morgan raises to overweight from neutral * Hubspot Inc HUBS.N : JP Morgan raises ta
A
C
G
D
L
A
A
C
I

Acadia Pharmaceuticals Q3 EPS USD 0.2 Vs. IBES Estimate USD 0.14

BRIEF-Acadia Pharmaceuticals Q3 EPS USD 0.2 Vs. IBES Estimate USD 0.14 Nov 06 (Reuters) - Acadia Pharmaceuticals Q3 operating expenses USD 218.757 million. Q3 net income USD 32.765 million vs. IBES estimate USD 24.5 million Q3 pretax profit USD 38.806 million vs. IBES estimate USD 27 million Q3 product sales USD 250.401 million vs. IBES estimate US
A

Neuren Pharmaceuticals tops benchmark after US partner sells FDA review voucher

BUZZ-Neuren Pharmaceuticals tops benchmark after US partner sells FDA review voucher ** Shares of Australia's Neuren Pharmaceuticals NEU.AX rise as much as 6% to A$13.00, marking their biggest intraday gain since Sept. 27 ** NEU top gainer in the ASX200 benchmark index .AXJO ** NEU, which develops therapies for neurodevelopmental disorders, says U.S.
A
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.